drugset / Trial / NCT05343572
Bone Marrow Derived Stem Cells Mobilization for Treatment of Abnormal Endometrium
NaSingle-groupOpen-labelTreatment
Summary
This study will assess the use of autologous bone marrow stem cells mobilization using 1,1'-\[1,4-phenylenebis-(methylene)\]-bis-1,4,8,11-tetraazacyclotetradecane (PLERIXAFOR) as an effective medical therapy for the treatment of Asherman's Syndrome (AS), Atrophic Endometrium (AE) and Recurrent Implantation Failure (RIF).
Timeline
- Start
- 2023-11-01
- Primary completion
- 2026-12
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Plerixafor | Small molecule | 0.24 mg/kg | Subcutaneous |
| Subject | Plerixafor | Small molecule | 20 mg | Subcutaneous |